Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Veradigm ( (MDRX) ) is now available.
On April 6, 2026, Veradigm announced it had appointed Christian Greyenbuhl as chief financial officer, effective on or after May 11, 2026, once the company becomes current with its 2023 and 2024 annual reports. Greyenbuhl, a veteran finance executive with experience at Ministry Brands, Xplor Technologies, ADP and PricewaterhouseCoopers, will also serve as principal financial and accounting officer, replacing interim CFO Lee Westerfield, who is expected to move into a consulting role to support the transition.
His compensation package includes a $580,000 base salary, a $300,000 sign-on bonus subject to clawback, a target bonus equal to 75% of base pay and an initial $3 million equity grant split between time-based restricted stock units and performance share units, alongside severance protections that provide cash, benefits and accelerated vesting if he is terminated without cause or resigns for good reason. In tandem with the CFO change, Veradigm is restructuring its leadership by ending the employment of interim finance chief Westerfield and general counsel Tejal Vakharia and expanding its 2024 stock incentive plan by 6 million shares to 17 million total, a move that underscores its reliance on equity-based pay to attract and retain executives as it executes a strategic “Reset, Recover, Reignite” plan and works to regain market leadership with independent physician practices.
The most recent analyst rating on (MDRX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Veradigm stock, see the MDRX Stock Forecast page.
More about Veradigm
Veradigm Inc., traded over the counter as MDRX, is a healthcare technology company that provides clinical and revenue cycle management solutions to independent physician practices. Its AI-enabled data and technology platforms connect more than 20,000 provider practices with health plans and biopharmaceutical companies to reduce inefficiencies, close care gaps and support a more affordable healthcare system.
The company focuses on helping independent practices improve clinical outcomes and financial performance while leveraging proprietary data assets to deliver actionable insights across the healthcare ecosystem. Veradigm positions itself as a leading player in the ambulatory health IT market, targeting mission-critical workflows and revenue optimization for community-based providers.
Average Trading Volume: 206,657
Technical Sentiment Signal: Strong Sell
Current Market Cap: $500.9M
For detailed information about MDRX stock, go to TipRanks’ Stock Analysis page.